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Anemia promotes intratumoral hypoxia, and in turn, hypoxia may adversely impact treatment outcomes by reducing the eﬀec-
tiveness of radiation therapy and by promoting molecular and cellular changes that favor malignant progression and formation of
metastases. Recent experimental and clinical studies have been aimed at further exploring the mechanisms by which anemia and
hypoxia exert their negative inﬂuence in order to identify the more eﬀective interventions to improve clinical prognosis and
outcomes. In a recent study of patients with squamous cell carcinoma of the oral cavity and oropharynx, pretreatment hemoglobin
(Hb) level and epoetin alfa therapy were independent prognostic factors for response to radiochemotherapy and locoregional tumor
control (P <0.01). Patients with pretreatment Hb levels 514.5 g/dl had signiﬁcantly (P 40.001–P <0.05) higher complete
response, 2-year locoregional control, and 2-year survival rates than patients with Hb levels <14.5 g/dl who had not received
epoetin alfa. Further, the response, locoregional control, and survival rates of epoetin alfa–treated patients with a pretreatment Hb
<14.5 g/dl were signiﬁcantly higher than those of patients with pretreatment Hb levels <14.5 g/dl not given epoetin alfa, and were
equivalent to those of patients with a pretreatment Hb level 514.5 g/dl. These observations and those of several other studies
suggest that stabilization of normal Hb levels and correction of treatment-related anemia may contribute to improved therapeutic
outcomes in cancer patients. Controlled prospective clinical trials in larger numbers of cancer patients are clearly warranted.
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The presence of hypoxia in solid tumors is a clinical
concern as it can negatively impact disease prognosis
and therapeutic outcome in patients with these malig-
nancies [1,2]. Notably, hypoxia can reduce the eﬀective-
ness of radiation therapy and some O2-dependent
cytotoxic agents. Additionally, hypoxia can promote
changes in the genome and proteome of tumor cells that
ultimately favor malignant progression and formation
of metastases [1,3].
Clinically relevant hypoxia is detected in approxi-
mately 50% of all solid tumors irrespective of their size
and histologic features. Tumor hypoxia results from an
imbalance between cellular oxygen (O2) consumption
and O2 supply to the cells [4]. The causes of tumorhypoxia are multifactorial and can include inadequate
blood ﬂow to the tumor due to structural and functional
abnormalities of the tumor microvasculature (perfusion-
limited or ‘acute’ hypoxia), or due to increased diﬀusion
distances subsequent to tumor expansion, which lead to
inadequate supply of O2 and other nutrients for cells
distant from the nutritive vessels (diﬀusion-limited or
‘chronic’ hypoxia). Tumor hypoxia can also be caused
by decreased O2 transport capacity of the blood as a
result of anemia, a frequent complication in cancer
patients, as well as methemoglobin formation or carbon
monoxide poisoning [4].2. Relationship of anemia to tumor hypoxia
Results of several experimental and clinical studies
suggest a relationship between declining hemoglobin
(Hb) levels and decreasing tumor oxygenation. In a
study that used a rat model of tumor-associated anemia,1359-6349/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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tumor oxygenation was poorer in anemic animals than
in normal animals, a condition that could be partially
reversed by administration of recombinant human
erythropoietin (rHuEPO, epoetin alfa) [5,6]. Also, in a
study in mice with radiation-induced chronic renal
failure, a strong correlation (r=0.57; P <0.001) was
detected between increased hematocrit and increases in
tumor oxygenation [7,8].
In the clinical setting, an association between
oxygenation and Hb level seems probable, but is not yet
completely clear, as variations have been found among
diﬀerent tumors [9]. A recent clinical study measured
tissue oxygen pressure (pO2) in squamous cell carcino-
mas and normal sternocleidomastoid muscles from 133
patients with head and neck cancer [10]. Patients were
grouped according to whether they had normal Hb
levels (512 g/dl in women and 513 g/dl in men), mild
anemia (Hb 511 g/dl but <12 or 13 g/dl), or severe
anemia (Hb <11 g/dl). In the normal tissue, the average
pretreatment median pO2 was 38 mm Hg (range 21–68
mm Hg) and decreasing Hb levels did not cause
signiﬁcant impairment of oxygenation in this tissue. In
comparison, the tumors were more poorly oxygenated,
having an average median pO2 of 12 mm Hg (range 0–
58 mm Hg). Although pO2 in the tumors did not diﬀer
signiﬁcantly between patients with mild anemia and
nonanemic patients, tumor oxygenation in patients with
moderate or severe anemia was signiﬁcantly reduced
relative to the other two patient groups (P <0.0001)
(Fig. 1), and nearly all tumors of patients with moderate
or severe anemia were hypoxic. Multivariate analysis
showed an Hb level <11 g/dl to be the strongest pre-
dictor of tumor hypoxia. These ﬁndings suggested that
tumors are less able than normal tissue to compensate
for anemia, and are therefore more prone to be hypoxic.
Also, a direct correlation has been found between Hblevel and median pO2 in breast cancer patients [11,12].
Correlations between Hb level and median pO2 or the
fraction of hypoxic pO2 values have not generally been
found in cancer of the uterine cervix [13,14]. However, a
study has demonstrated signiﬁcantly (P=0.05) lower
pO2 values in cervical cancer patients with severe
anemia (Hb 411 g/dl) than in those without anemia
(Hb >14 g/dl) [15]. Further, in a study that examined
radiation-induced changes in pO2 in cervical cancer
patients, a baseline Hb level <13 g/dl, compared with a
level 513 g/dl, was associated with signiﬁcantly poorer
oxygenation (median pO2 12.4 mm Hg versus 28.1 mm
Hg; P=0.003) and a signiﬁcantly higher rate of
treatment failure after 1 year (56% versus 22%;
P=0.046) [16]. Together, these ﬁndings clearly prove a
relationship between lower Hb levels, increased
hypoxia, and a negative impact of anemia/hypoxia on
treatment outcome.3. Impact of hypoxia on tumor biology and treatment
resistance
3.1. Impact on tumor biology
Hypoxia can inﬂuence tumor cells by acting as a
stressor that impairs growth or causes cell death (apop-
tosis or necrosis). Or it can inﬂuence tumor cells by
driving processes that ultimately further malignant
progression and increased resistance of the tumor to
radiation therapy and some forms of chemotherapy
[9,17]. These eﬀects variously reﬂect hypoxia-induced
changes in the proteome and genome of the tumor cells.
Hypoxia-induced changes of the proteome may lead
to growth impairment or death through molecular
mechanisms that result in cellular quiescence, diﬀer-
entiation, and apoptosis [18]. Alternatively, hypoxia-
induced proteome changes may activate anerobic
metabolism, angiogenesis, change of cell contacts, and
other processes that promote survival and propagation
by enabling the tumor cells to adapt to or escape from
their hostile environment. For example, hypoxia leads
to upregulation of glycolytic enzymes and the glucose
transporters GLUT1 and GLUT2; of growth factors
including vascular endothelial growth factor (VEGF),
erythropoietin and endothelial growth factor; and of
enzymes and other proteins involved in tumor invasive-
ness, such as urokinase-type plasminogen activator.
Additionally, hypoxia may lead to downregulation of
cell-surface integrins, which facilitates tumor cell
detachment.
Importantly, the phenotypic results of the hypoxia-
induced proteome changes appear to be determined by
the genome of the tumor cells, in addition to environ-
mental factors [18]. The existence of a tumor cell
population with genomic alterations (e.g. decreasedFig. 1. Oxygenation of normal tissue (sternocleidomastoid muscle) or
head and neck tumors. Patients were grouped according to their
hemoglobin (Hb) levels. The histograms depict the range of pO2 values
in normal tissues and tumors, and the line shows the median values.
Reprinted with permission [10].4 J. Dunst / EJC Supplements Vol 2 No. 2 (2004) 3–10
capacity for cell-cycle arrest, loss of apoptotic potential,
increased angiogenic potential) that allow their survival
in a hypoxic environment furthers tumor hypoxia.
Sustained hypoxia, in turn, increases genomic instabil-
ity, genomic heterogeneity, and selection for cell
variants better adapted to a hypoxic environment, with
eventual consequences for malignant progression and
treatment resistance.
3.2. Genomic instability
As indicated above, hypoxia favors genomic
instability. This is evidenced by the observation that
hypoxia induces fragile chromosomal sites, leading to
gene ampliﬁcation and genome rearrangements [19].
Fragile sites have long been recognized as a chromo-
somal expression of genomic instability. Also, the
impact of hypoxia on genetic stability was demonstrated
in a classic study reported in 1996 [20]. In this study,
cells from a tumorigenic cell line were grown con-
currently either in culture or as tumors in nude mice.
Oxygen tension measurements showed that all develop-
ing tumors in the mice contained numerous hypoxic
areas. The frequency of mutation in the cells that arose
within the mouse tumors was 5 times higher than that in
the cultured cells (P <0.0001). Distinctive mutation
patterns were also observed, with tumor-grown cells
displaying more deletions and transversions than the
cells grown in culture. Of particular interest, exposure
of the cultured cells to hypoxic conditions resulted in an
increase in mutation frequency and a mutation pattern
similar to that observed in the tumor-grown cells. These
ﬁndings support the hypothesis that the genetic
instability of malignant tumors may be due at least
partially to speciﬁc mutagenic properties of the hypoxic
environment [21].
3.3. Genome changes, clonal selection and malignant
progression
The genome of tumor cells is less stable than that of
normal cells, a condition reﬂected by a high rate of
point mutations, gene ampliﬁcations, deletions, and
chromosomal rearrangements [22]. Hypoxia, with or
without reoxygenation, promotes genomic instability,
and thus may increase the number of mutations (genetic
variants).
Point mutations may be generated in tumor cells
exposed to hypoxia and reoxygenation via several
mechanisms including diminished DNA repair, errors in
DNA replication, metabolic damage of DNA bases, or
any combination of these factors [20,23]. Also, as
demonstrated in the study of fragile sites [19], hypoxia
followed by reoxygenation can lead to gene ampliﬁcation.
Both ampliﬁcation and chromosomal rearrangements
can be caused by DNA strand breakage or diminishedrepair of DNA strand breaks [22]. Hypoxia-induced
genome changes may, in turn, promote metastatic
disease by inactivating metastasis suppressor genes or
enhancing expression of genes involved in the metastatic
process, e.g. genes encoding for angiogenesis.
In addition to increasing the number of genetic
variants, hypoxia concomitantly exerts a strong selection
pressure on tumor cells [4,17,18,24]. Thus, any tumor
cells with proteomic or genomic adaptations that
enhance survival under hypoxic conditions (e.g.
decreased apoptosis potential, increased angiogenesis
potential) will have growth advantages over nonadapted
cells. These adapted cells expand through clonal selec-
tion, i.e. their progeny proliferate at a rate exceeding
that of the progeny of the non adapted cells, and even-
tually become the dominant tumor sub population. The
adapted cells also tend to have favorable traits related
to invasiveness, metastatic capability and aggressiveness
which, in the clinical setting, manifest as increased local
recurrence, metastasis and increased resistance to treat-
ment. The expansion of cell clones with favorable
adaptive changes can further aggravate tumor hypoxia,
thereby establishing a vicious circle of hypoxia,
malignant progression and treatment resistance that
underlies advanced (and usually incurable) disease.
3.4. Resistance to radiation therapy
Hypoxia directly decreases the eﬀectiveness of radia-
tion therapy, presumably as a result of the low intratu-
moral concentrations of molecular O2. The precise
mechanism involved remains unclear. According to one
hypothesis, the presence of O2 increases the breakage of
DNA strands via formation of O2-derived free radicals,
which occurs primarily after interaction of ionizing
radiation with intracellular water [1,9,25,26]. Thus, in
the absence of adequate O2, radiation-induced DNA
damage and subsequent cell death are less likely to
occur. Alternatively, O2 may ‘ﬁx’ (make permanent or
unrepairable) the DNA breakage caused by free
radicals, again resulting in cell death. However, under
hypoxic conditions, the damage can be repaired, thus
negating the cytotoxic eﬀects of radiation therapy.
The impact of hypoxia on the eﬀectiveness of a cancer
treatment is reﬂected by the treatment’s oxygen
enhancement ratio (OER). In 1951, Hollaender et al.
reported that the radiation dose required to eradicate
Escherichia coli under anoxic conditions was three times
that required under normoxic conditions [27]. This
ﬁnding led to the development of the OER for photons
(X-rays), neutrons, and heavy ions, the OER being
deﬁned as the ratio of the radiation dose needed to
achieve the same cell survival fraction under hypoxic
conditions as under normoxic conditions [26]. Because
of the oxygen enhancement eﬀect, the oxygen enhance-
ment ratio for photon therapy is about 3, indicating thatJ. Dunst / EJC Supplements Vol 2 No. 2 (2004) 3–10 5
3-fold higher doses of radiation are needed to kill
hypoxic cells compared with normoxic ones. However,
even with the higher doses, some cells survive and can
re-establish tumors at the site of the original malignancy
or in distant areas [28]. With fractionated radiotherapy,
the situation is more complex, since cells can be
reoxygenated between treatments. With reoxygenation,
radiosensitivity is restored, thereby increasing the
responsiveness of the tumor to subsequent radiation
therapy. However, reoxygenation does not occur con-
sistently across all cells, and some cells may reoxygenate
less rapidly and extensively. These cells are thus still
relatively resistant to radiation, and form a pool of cells
that continue to proliferate, thereby limiting the
eﬀectiveness of radiation therapy [28].
In addition to directly enhancing resistance to radia-
tion therapy, hypoxia may indirectly accomplish this via
proteome and genome changes, and clonal selection.
For example, hypoxia-induced proteome changes may
lead to elevated levels of DNA repair enzymes, while
genome changes may result in loss of apoptosis poten-
tial and emergence of resistant clonal variants. Table 1
summarizes a number of direct and indirect eﬀects of
hypoxia that result in acquired treatment resistance to
radiation therapy (a) or chemotherapy (b).
3.5. Resistance to chemotherapy
As in the case of radiation therapy, the eﬀectiveness
of some chemotherapeutic agents can be reduced
directly by decreased generation of free radicals in a
hypoxic cellular environment, which limits DNA
damage by such agents (e.g. bleomycin and anthracy-
clines). Indirectly, poor and ﬂuctuating blood ﬂow due
to structural or functional abnormalities of the tumor
blood vessels, as well as the limited diﬀusion distance
through tumor tissue, can result in reduced and erratic
distribution of chemotherapeutic agents, with subse-
quently reduced eﬀectiveness [29,30]. Also, some agents,
e.g. cyclophosphamide, carboplatin and doxorubicin,
have been shown to be oxygen-dependent under experi-
mental conditions [28,31–33]. One proposed explana-
tory mechanism is increased production of nucleophilic
substances such as glutathione, which can compete with
the target DNA for alkylation (as reﬂected in the
acquired resistance to alkylating agents); another is
increased activity of DNA repair enzymes, which can
diminish the eﬃcacy of alkylating agents and platinum
compounds (Table 1b) [9].4. The role of VEGF in angiogenesis
Angiogenesis is a complex process in which new blood
vessels develop from existing vasculature (neovascular-
isation), thereby providing a conduit for blood ﬂow inexpanding cell populations, including those of tumor
tissue. Angiogenesis is a major prognostic factor for the
promotion of malignant disease and the formation of
metastases [34,35].
The angiogenic process is regulated by several
cytokines. The most important of these is VEGF, and
the most important stimulus for secretion of this factor
is tumor hypoxia or ischemia. Elevated levels of VEGF
appear to reﬂect increased angiogenic activity and are
associated with poor prognosis in a variety of malig-
nancies [36–38]. Nevertheless, the impact of anemia on
increased levels of angiogenic cytokines in patients with
metastatic disease has not been investigated.
In a recent study, serum levels of VEGF were
determined in 56 patients with previously untreated,
locoregionally conﬁned gynecologic, head and neck,
gastrointestinal, lung or prostate carcinomas [39].
VEGF levels were signiﬁcantly higher in 26 patients
with Hb levels <13 g/dl compared with the 30 patients
with normal Hb levels 513 g/dl (805 versus 438 pg/ml,
P=0.016) (Fig. 2). All patients without anemia had
VEGF levels within the normal range. Other variables,
including patient age and tumor stage, size, site, grade
and histology, were unrelated to VEGF levels. These
ﬁndings are consistent with the hypothesis that low Hb
levels promote intratumoral hypoxia, which in turn
triggers the release of VEGF. This hypothesis infers that
anemia may have the potential to stimulate angiogenesis
by causing intratumoral hypoxia; however, further
investigation is needed to determine if this hypothesis
has any therapeutic signiﬁcance.5. Improving prognosis by treating anemia
The prognostic signiﬁcance of anemia in patients
with solid tumors is illustrated by the results of a
recent retrospective study conducted at seven Canadian
institutions [40]. The outcomes of 605 patients withFig. 2. Serum levels of VEGF in 56 consecutive patients with
previously untreated, locoregionally conﬁned gynecologic, head and
neck, gastrointestinal, lung, or prostate carcinomas. Patients are
grouped according to their hemoglobin (Hb) levels. VEGF, vascular
endothelial growth factor. Reprinted with permission [39].6 J. Dunst / EJC Supplements Vol 2 No. 2 (2004) 3–10
cervical cancer who received radical radiation therapy at
doses 535 Gy were reviewed. Patients receiving deﬁni-
tive surgery, neoadjuvant chemotherapy, or epoetin alfa
were excluded. Patients were grouped according to
whether they had low (<12 g/dl) or normal (512 g/dl)
Hb levels at the beginning and end of radiation therapy.
Patients with normal Hb levels at both determinations
had a 5-year survival rate of 74%, whereas those with
low Hb levels at both had a survival rate of 51% (P
<0.002). A group of 25 patients with low Hb at the
start of radiation therapy received transfusions tocorrect their anemia and had normal Hb levels by the end
of therapy. In this small group, the 5-year survival rate
was 70%, which did not diﬀer signiﬁcantly from that of
patients who started and remained at normal Hb levels.
In the subgroup of 82 patients who presented with nor-
mal Hb levels (512 g/dl) but whose levels fell below 12
g/dl during radiation therapy, the 5-year survival rate
was signiﬁcantly reduced to 50% (P=0.0118). Overall,
the diﬀerence in survival between patients with low and
normal Hb levels at the end of radiation therapy
remained signiﬁcant even after adjustment for otherTable 1




 Through reduced ‘ﬁxation’ of DNA damage (X- and g-rays)
Indirect eﬀects (related to proteome changesa)
 Slowing of proliferation kinetics
 G1-/S-phase arrest; increase in number of cells in G0 phase
 Elevated levels of glutathione and related thiols
 Elevated levels of DNA repair enzymes and of resistance-related proteins
Indirect eﬀects (related to genome changesb and clonal selection)
 Loss of apoptosis and diﬀerentiation
 Clonal heterogeneity
 Proliferation of resistant clonal variants
 Increase in number of cells with aggressive phenotype
Secondary indirect eﬀects (related to intensiﬁed glycolysis and extracellular acidosis)
 Cell-cycle eﬀects
 Activation of repair processes(b) Chemotherapy
Direct eﬀects
 Through decreased generation of free radicals, and thus, less DNA damage (bleomycin, anthracyclines)
Indirect eﬀects (related to proteome changes)
 Slowing of proliferation kinetics; increase in number of cells in G0 phase
 G1-/S-phase arrest (e.g. vinca alkaloids, methotrexate)
 Elevated levels of glutathione and DNA repair enzymes (alkylating agents, bleomycin, platinum compounds)
Indirect eﬀects (related to genome changes and clonal selection)
 Loss of apoptosis and diﬀerentiation
 Clonal heterogeneity
 Proliferation of resistant clonal variants
 Increase in number of cells with aggressive phenotype
Secondary indirect eﬀects (related to intensiﬁed glycolysis with extracellular acidosis)
 Transport of drugs across the cell membrane
 Intracellular drug accumulation Weak acids " (e.g. melphalan, mitomycin C)
 Weak bases # (e.g. anthracyclines, bleomycin) Drug activity
 " Cyclophosphamide, cisplatin, melphalan
 # Vinblastine, doxorubicin, bleomycin Activation of prodrugs
Secondary indirect eﬀects (related to chaotic angiogenesis and impact of microcirculation on intratumor pharmacokinetics)
 Impaired and uneven drug delivery
 Arteriovenous shunt perfusion
 Large diﬀusion distancesa Resulting from modulation of gene expression, posttranscriptional eﬀects, and/or posttranslational eﬀects.
b Through point mutations, gene ampliﬁcation, and/or chromosomal rearrangements.J. Dunst / EJC Supplements Vol 2 No. 2 (2004) 3–10 7
prognostic factors, such as tumor stage and histology (P
<0.0002). The overall tumor recurrence rate was sig-
niﬁcantly lower for patients whose Hb levels remained
within the normal range during radiation therapy com-
pared with those whose levels fell below 12 g/dl (33%
versus 58%, P=0.001). These patients also had
signiﬁcantly lower pelvic failure rates (P <0.0001). This
ﬁnding is consistent with the impact of anemia on
tumor hypoxia, inasmuch as these patients had received
radiation as a local treatment. Patients with normal Hb
levels (512 g/dl) additionally had signiﬁcantly lower
rates of distant metastases (P <0.0006), a ﬁnding that
was independent of the pelvic failure rate.
In another retrospective study, which included 847
patients with squamous cell carcinoma of the supra-
glottic larynx, Hb levels after radiotherapy were at least
as important as overall treatment time as a prognostic
factor for outcome [41]. After a minimum follow-up of
3 years, Hb levels were strongly correlated with the
probability of local tumor control. Hemoglobin levels at
the start of radiotherapy did not correlate with treat-
ment outcome, but any decrease in Hb levels during
therapy was a strong prognostic factor for treatment
failure.
Although these studies were not designed pro-
spectively, the results suggest that Hb levels during and
at the end of radiation therapy have prognostic sig-
niﬁcance with respect to tumor recurrence and survival.
Even if the beneﬁt of treating anemia were actually only
half as large as suggested by the retrospective analyses
of patients with cervical cancer, it would still be greater
than the impact of adjuvant chemotherapy on survival
of breast cancer patients, which is well recognized as a
standard of care.6. Eﬀect of epoetin alfa on treatment outcomes
The optimal strategy for treating anemia as a means
to improve outcomes after radiation therapy or radio-
chemotherapy remains to be deﬁned in controlled
clinical trials. Epoetin alfa is a recombinant human
glycoprotein with an amino acid sequence identical to
isolated natural erythropoietin [42]. In cancer patients
with anemia, epoetin alfa is eﬀective in reducing trans-
fusion requirements, maintaining adequate Hb levels,
managing fatigue, and improving overall quality of life
[43–47].
The inﬂuence of epoetin alfa therapy and Hb level on
therapeutic response, locoregional tumor control, and
overall survival was retrospectively assessed in 191
patients who received neoadjuvant chemoradiotherapy
and surgery for squamous cell carcinoma of the oral
cavity and oropharynx at the General Hospital Vienna,
Austria, between November 1989 and October 1998
[42]. The patients were treated with mitomycin C (15mg/m2 on day 1), 5-ﬂuorouracil (750 mg/m2/day, days
1–5), and radiotherapy (50 Gy in 25 fractions during
weeks 1–5), followed by resection of the primary tumor
and regional cervical lymphatics at week 10 or 11.
Beginning in May 1996, patients with a low Hb level
before or during chemotherapy received epoetin alfa 10
000 IU/kg subcutaneously three times a week until the
week of surgery. The frequency of epoetin alfa admin-
istration was increased to six times weekly in patients
whose Hb did not rise by at least 0.3 g/dl during the ﬁrst
treatment week. For data analysis, the patients were
divided into four groups according to whether their
pretreatment Hb level was <14.5 or 514.5 g/dl and
whether or not they had received epoetin alfa during
neoadjuvant radiochemotherapy. Results of multi-
variate analysis indicated that the use of epoetin alfa
and pretreatment Hb level were independent prognostic
factors for response to chemoradiotherapy and locor-
egional tumor control (P <0.01). Patients with pre-
treatment Hb levels 514.5 g/dl had signiﬁcantly (P
40.001–P <0.05) higher complete response, 2-year
locoregional control, and 2-year survival rates than
patients with Hb levels <14.5 g/dl who had not received
epoetin alfa. Moreover, epoetin alfa-treated patients
with a pretreatment Hb level <14.5 g/dl had response,
locoregional control, and survival rates that were
signiﬁcantly (P 40.001) higher than those for patients
with pretreatment Hb levels <14.5 g/dl not given epoe-
tin alfa and that were equivalent to those of patients
with a pretreatment Hb level >14.5 g/dl (P 50.30)
(Table 2, Fig. 3). These ﬁndings conﬁrmed those of
other studies that suggested that low Hb levels are a
negative prognostic factor for response to cancer ther-
apy. These ﬁndings also demonstrated that the negative
inﬂuence of low Hb levels can be reversed by epoetin
alfa administration during neoadjuvant chemoradio-
therapy.Fig. 3. Overall survival of patients with oral squamous cell carcinoma
following radiochemotherapy. In this retrospective study, complete
response, survival, and locoregional control were compared between 4
groups of patients categorized by Hb level <14.5 g/dl or 514.5 g/dl,
and whether or not they had received epoetin alfa therapy. Reprinted
with permission [47].8 J. Dunst / EJC Supplements Vol 2 No. 2 (2004) 3–10
The eﬀect of epoetin alfa on treatment outcomes was
also evaluated in a Greek study that included 385
patients with pelvic malignancies who were undergoing
deﬁnitive radiation therapy [48,49]. Patients were
randomly assigned to receive epoetin alfa sub-
cutaneously ﬁve times per week with iron supplements
or iron supplements alone (control group). Patients
received radiation therapy at a dose of 2 Gy daily, with
the total dose determined by the site and stage of
disease. At baseline, the two treatment arms were well
matched with respect to age, Hb levels, and site and
stage of disease. The group that received epoetin alfa
had signiﬁcantly higher mean Hb levels during radiation
therapy compared with the control group (12.92.6 g/dl
versus 10.62.5 g/dl; P=0.0001). The 4-year disease-
free survival rate was 85.3% in patients treated with
epoetin alfa versus 67.2% in control patients
(P=0.0008) [49].7. Conclusion
It is well recognized that both anemia and tumor
hypoxia have prognostic signiﬁcance in patients with
solid tumors and that hypoxia is an important stimulus
for angiogenesis. Results of recent studies suggest that
anemia promotes tumor hypoxia, partly explaining the
unfavorable prognostic signiﬁcance of anemia. More-
over, anemia was associated with increased serum
VEGF levels, suggesting that it may also contribute to
angiogenesis. In patients receiving radiation therapy or
radiochemotherapy, Hb level at the end of treatment
had prognostic signiﬁcance in terms of survival and
tumor recurrence. The Hb level at the end of treatment
appears to be at least as important as the pretreatment
level, if not more important, in predicting outcome.
Accordingly, stabilization of normal Hb levels and
prevention of treatment-related anemia is likely to be
desirable. The results of preliminary studies show that
epoetin alfa was eﬀective in increasing Hb levels in patients
receiving radiation therapy or radiochemotherapy.
However, more importantly, these studies suggest that
treatment of anemia with epoetin alfa may increase local
disease control and improve overall survival.Controlled clinical trials involving larger numbers of
cancer patients are clearly warranted. The strategy used in
these studies should be to assess the value of maintaining
Hb levels within a normal range during radiation ther-
apy and radiochemotherapy and of achieving a normal
range by the end of such treatment. Control of anemia
should be achieved with epoetin alfa but, if this goal is
not reached, then additional transfusions should be
considered. On the basis of available evidence, it is
likely that most patients presenting with normal Hb
levels or mild-to-moderate anemia will respond to
epoetin alfa and will not require transfusions. However,
it is still unclear whether patients presenting with severe
anemia will have suﬃcient increases in Hb over the 6- to
8-week course of radiation therapy to reach normal Hb
levels by the end of treatment.References
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